Kala Bio (KALA) EBITDA Margin (2019 - 2022)
Kala Bio's (KALA) quarterly EBITDA Margin came in at 3468.81% in Q3 2022, down 261876.0% year-over-year from N/an in Q3 2021, and down 180.48% quarter-over-quarter from 1236.76% in Q2 2022.
Powered by 
Analysis
Kala Bio (KALA) EBITDA Margin (2019 - 2022) Analysis & Trends
Kala Bio has disclosed EBITDA Margin across 4 years of filings, most recently posting 3468.81% for Q3 2022.
- In Q3 2022, EBITDA Margin fell 261876.0% year-over-year to 3468.81%; the TTM figure through Dec 2022 stood at 2099.33% (down 94057.0% YoY), while the FY2022 annual figure was 2099.33%, down 94057.0% from the prior year.
- EBITDA Margin came in at 3468.81% for Q3 2022 at Kala Bio, down from 1236.76% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 850.05% in Q3 2021 to a low of 3468.81% in Q3 2022.
- Average EBITDA Margin over 4 years is 1671.04%, with a median of 1486.35% recorded in 2019.
- Year-over-year, EBITDA Margin soared 160264 bps in 2021 and tumbled 261876 bps in 2022.
- Over 4 years, EBITDA Margin stood at 1711.61% in 2019, then grew by 24 bps to 1295.08% in 2020, then tumbled by 95 bps to 2522.36% in 2021, then tumbled by 38 bps to 3468.81% in 2022.
- Per Business Quant data, the three most recent EBITDA Margin figures were 3468.81% in Q3 2022, 1236.76% in Q2 2022, and 2253.21% in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.55 Bn | 192.56 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.15 Bn | 176.98 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.59 Bn | 123.73 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.98 Bn | 73.98 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.33 Bn | 55.14 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.75 Bn | 48.61 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.95 Bn | 30.67 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.25 Bn | 29.25 Bn | 1.16 Mn | -25,380.93% |
| 10 | Kala Bio | 8.44 Mn | 8.44 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -3,468.81% |
| Jun 30, 2022 | -1,236.76% |
| Mar 31, 2022 | -2,253.21% |
| Dec 31, 2021 | -2,522.36% |
| Sep 30, 2021 | -850.05% |
| Jun 30, 2021 | -951.98% |
| Mar 31, 2021 | -866.93% |
| Dec 31, 2020 | -1,295.08% |
| Sep 30, 2020 | -1,164.05% |
| Jun 30, 2020 | -2,554.62% |
| Mar 31, 2020 | -1,879.08% |
| Dec 31, 2019 | -1,711.61% |
| Sep 30, 2019 | -1,486.35% |
| Jun 30, 2019 | -1,089.45% |
| Mar 31, 2019 | -1,735.21% |